Fiche publication
Date publication
février 2022
Journal
International journal of pharmaceutics
Auteurs
Membres identifiés du Cancéropôle Est :
Dr FRISCH Benoit
,
Dr HEURTAULT Béatrice
Tous les auteurs :
Labrak Y, Heurtault B, Frisch B, Saulnier P, Lepeltier E, Miron VE, Muccioli GG, des Rieux A
Lien Pubmed
Résumé
Impairment of oligodendrocyte progenitor cell (OPC) differentiation into oligodendrocytes and chronic inflammation are key determinants of poor remyelination observed in diseases such as multiple sclerosis. For many pro-myelinating molecules, the therapeutic potential is hindered by poor solubility or limited access to the targeted cells. A promising approach to improve the delivery of those molecules to OPC is to encapsulate them in functionalized Lipid Nanocapsules (LNC). We aimed to develop the first OPC-targeting LNC, by grafting an anti-PDGFRα antibody on the surface of the LNC using several strategies and evaluating the interaction with PDGFRα via ELISA. We found that only site-selective click-chemistry grafting maintained anti-PDGFRα/PDGFRα association, confirmed in vitro on primary rat OPC. In conclusion, we demonstrated that it was possible to produce anti-PDGFRα functionalized LNC, confirmed the antibody's ability to recognize its receptor after grafting and optimized techniques to characterize antibody functionalized LNC.
Mots clés
Lipid nanocapsules, Multiple sclerosis, Nanomedicine Remyelination, Surface modification
Référence
Int J Pharm. 2022 Feb 26;:121623
